Results from three two-year studies showed that Exubera ( Human Insulin Powder ), an inhalable, short-acting, dry powder Insulin, provided effective, sustained glycemic control and was well tolerated over two years in adults with type 2 diabetes.
A fourth study showed that three months of Exubera therapy was well tolerated and as effective as subcutaneous short-acting insulin in achieving tight glycemic control in adults with type 1 diabetes.

A pooled analysis of two Phase 3 studies involving 304 adults with type 2 diabetes showed that people who added Exubera to their treatment regimen maintained glycemic control for the two-year period and experienced no clinically important effects on pulmonary function compared to patients treated with oral agents alone.
An additional analysis from a third study of 384 adults treated with Exubera during a two-year open-label extension further supported these findings.

" These studies showed that Exubera provided effective glycemic control and was well tolerated in adults with type 2 diabetes, " said William Cefalu, lead study investigator and at Pennington Biomedical Research Center, Louisiana State University System.

A separate study involving 226 adults with type 1 diabetes showed that Exubera was well tolerated and as effective as subcutaneous, short-acting Insulin in achieving tight glycemic control.
Those who received Exubera for three months demonstrated improved glycemic control from baseline and experienced no clinically important effects on pulmonary function compared to adults treated with subcutaneous Insulin alone.
Baseline glycemic ( A1C control was 7.5 percent.
At week 12, patients treated with Exubera achieved a glucose level of 7.1 percent, compared with 7.0 percent for patients receiving subcutaneous Insulin.

The most common adverse events reported in the trials were hypoglycemia and cough.
In two of the three studies in people with type 2 diabetes, hypoglycemia associated with inhaled Insulin therapy was comparable to treatment with non-inhaled antidiabetic agents.
Hypoglycemia rates were higher in the third study in people with type 2 diabetes, but in the setting of better glycemic control.
In the fourth study in people with type 1 diabetes, hypoglycemia rates were comparable between the group receiving inhaled insulin and subcutaneous Insulin and the group receiving subcutaneous Insulin alone. Cough was generally mild and did not lead to discontinuation.

Source: American Diabetes Association’s ( ADA ) 65th Annual Scientific Sessions, 2005


XagenaMedicine2005